Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.

ABSTRACT: Histone deacetylase inhibitors (HDACi) have been successfully used as monotherapies for the treatment of hematological malignancies; however, the single agent effects of HDACi against solid tumors are less robust. Using preclinical models of lymphoma, we have recently demonstrated that HDACi induce tumor cell-specific apoptosis and that this is essential for the therapeutic effects of these agents. Herein, we demonstrate that HDACi can be combined with immune-activating antibodies designed to promote the function of antigen-presenting cells (APCs) and enhance proliferation and survival of cytotoxic T cells (CTL) to stimulate a host antitumor immune response resulting in eradication of established solid tumors. This unique combination therapy was dependent on tumor cell apoptosis mediated b

SUBMITTER: Christiansen AJ 

PROVIDER: S-EPMC3054015 | biostudies-literature | 2011 Mar

REPOSITORIES: biostudies-literature